Clinical Trial: Action Outcome Latencies as a Measure of Sense of Agency in Functional Movement Disorders.

U.S., Dec. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07302308) titled 'Action Outcome Latencies as a Measure of Sense of Agency in Functional Movement Disorders.' on Dec. 11.

Brief Summary: Functional movement disorders (FMD) are among the most common neurological conditions seen in clinical practice, yet they are poorly understood and often misdiagnosed. Impaired self-agency, the sense of controlling one's actions, is a key feature of FMD. Studies using functional MRI have shown reduced activation and connectivity in the right inferior parietal lobule, a region associated with agency.

The sense of agency consists of two components: the feeling of agency, which is an implicit, low-level sense of contr...